Lenalidomide for the treatment of relapsed and refractory multiple myeloma
Niels WCJ van de Donk,1,2 Güllü Görgün,1 Richard WJ Groen,1,3 Jana Jakubikova,1 Constantine S Mitsiades,1 Teru Hideshima,1 Jacob Laubach,1 Inger S Nijhof,2 Reinier A Raymakers,2 Henk M Lokhorst,2 Paul G Richardson,1 Kenneth C Anderson11Department o...
Main Authors: | van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-08-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/lenalidomide-for-the-treatment-of-relapsed-and-refractory-multiple-mye-a10695 |
Similar Items
-
Bortezomib in the management of multiple myeloma
by: Jacob P Laubach, et al.
Published: (2009-09-01) -
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
by: Jacob P. Laubach, et al.
Published: (2021-02-01) -
Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01) -
Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01) -
Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)